G
Georg Kunz
Publications - 19
Citations - 2192
Georg Kunz is an academic researcher. The author has contributed to research in topics: Breast cancer & Epirubicin. The author has an hindex of 12, co-authored 19 publications receiving 1973 citations.
Papers
More filters
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga,José Baselga,Ian Bradbury,Holger Eidtmann,Serena Di Cosimo,Serena Di Cosimo,Evandro de Azambuja,Claudia Aura,Henry L. Gomez,Phuong Dinh,Karine Fauria,Veerle Van Dooren,Gursel Aktan,Aron Goldhirsch,Tsai Wang Chang,Zsolt Horváth,Maria Antonia Coccia-Portugal,Julien Domont,Ling Min Tseng,Georg Kunz,Joohyuk Sohn,Vladimir Semiglazov,Guillermo Lerzo,Marketa Palacova,Volodymyr Probachai,Lajos Pusztai,Michael Untch,Richard D. Gelber,Martine Piccart-Gebhart +28 more
TL;DR: Dual inhibition of Her2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting, and the two anti-HER2 agents given together would be better than single-agent therapy.
Journal ArticleDOI
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Gunter von Minckwitz,Holger Eidtmann,Mahdi Rezai,Peter A. Fasching,Hans Tesch,Holm Eggemann,Iris Schrader,K Kittel,Claus Hanusch,Rolf Kreienberg,Christine Solbach,Bernd Gerber,Christian Jackisch,Georg Kunz,Jens-Uwe Blohmer,Jens Huober,Maik Hauschild,Tanja Fehm,Berit Maria Müller,Carsten Denkert,Sibylle Loibl,Valentina Nekljudova,Michael Untch +22 more
TL;DR: The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response among patients with HER2-negative early-stage breast cancer.
Journal ArticleDOI
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
Yasmin Issa-Nummer,Silvia Darb-Esfahani,Sibylle Loibl,Georg Kunz,Valentina Nekljudova,Iris Schrader,Bruno Valentin Sinn,Hans-Ullrich Ulmer,Ralf Kronenwett,Marianne Just,Thorsten Kühn,Kurt Diebold,Michael Untch,Frank Holms,Jens-Uwe Blohmer,Jörg-Olaf Habeck,Manfred Dietel,Friedrich Overkamp,Petra Krabisch,Gunter von Minckwitz,Carsten Denkert +20 more
TL;DR: The lymphocytic infiltrate is a promising additional parameter for histopathological evaluation of breast cancer core biopsies and prospectively validated in an independent cohort that an increased immunological infiltrate in breast tumor tissue is predictive for response to anthracycline/taxane-based NACT.
Journal ArticleDOI
Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Bernd Gerber,S. Loibl,H Eidtmann,Mahdi Rezai,Peter A. Fasching,Hans Tesch,Holm Eggemann,Iris Schrader,K Kittel,Claus Hanusch,R. Kreienberg,Christine Solbach,C. Jackisch,Georg Kunz,J-U Blohmer,Jens Huober,Maik Hauschild,Valentina Nekljudova,Michael Untch,G. von Minckwitz +19 more
TL;DR: The addition of bevacizumab to chemotherapy in TNBC significantly increases pCR rates and lower tumor stage and grade 3 tumors were confirmed as independent predictors of higher pCR in multivariate logistic regression analysis.
Journal ArticleDOI
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
Christian Jackisch,Roberto Hegg,Daniil Stroyakovskiy,Jin-Seok Ahn,Bohuslav Melichar,Shin-Cheh Chen,Sung-Bae Kim,Mikhail Lichinitser,Elżbieta Starosławska,Georg Kunz,Silvia Falcon,Shou-Tung Chen,A. Crepelle-Flechais,Dominik Heinzmann,M. Shing,Xavier Pivot +15 more
TL;DR: Long-term efficacy supports the established non-inferiority of subcutaneous trastuzumab, and its safety profile remains consistent with the known intravenous profile.